Coley Stock Plunges As Pfizer Abandons NSCLC Program June 21, 2007 By Glen Harris Shares of Coley Pharmaceutical Group Inc. sank nearly 60 percent Wednesday on news that partner Pfizer Inc. has walked away from the investigation lung cancer drug PF-3512676, shelving two Phase III and two Phase II trials. (BioWorld Today)Read More
RSS